Cisatracurium Preparation and Dosing for Mechanically Ventilated Patients
For adult mechanically ventilated patients requiring neuromuscular blockade, initiate cisatracurium with a loading dose of 0.1-0.2 mg/kg followed by a continuous infusion starting at 2.5-3 mcg/kg/min, with the infusion rate adjusted based on clinical assessment and train-of-four monitoring to maintain 1-2 twitches. 1
Initial Loading Dose
- Bolus dose: 0.1-0.2 mg/kg administered intravenously over 5-10 seconds 1, 2
- This produces paralysis in approximately 2.5 minutes with recovery beginning around 25 minutes 1
- No dose adjustment needed for renal or hepatic dysfunction due to organ-independent Hofmann elimination 1
Continuous Infusion Preparation
Standard concentration options:
- 0.1 mg/mL (10 mg/100 mL) - dilute in compatible IV solution 2
- 0.4 mg/mL (40 mg/100 mL) - for higher concentration needs 2
The drug should be diluted in normal saline, 5% dextrose, or other compatible solutions and administered via precision infusion device 2.
Maintenance Infusion Dosing
Starting infusion rate: 2.5-3 mcg/kg/min 1, 2
- Begin infusion only after early evidence of spontaneous recovery from the loading dose 2
- An initial rate of 3 mcg/kg/min may be required to rapidly counteract spontaneous recovery 2
- Thereafter, 1-2 mcg/kg/min typically maintains adequate blockade (89-99% suppression) 2
Dosing Range in Clinical Practice
Clinical trials demonstrate that infusion rates in ICU patients range from 0.5 to 10.2 mcg/kg/min, with most patients requiring approximately 3 mcg/kg/min 2. Studies specifically show:
- Mean infusion rate: 2.3-3.1 mcg/kg/min in critically ill patients 3, 4, 5
- This is approximately one-third the infusion rate required for atracurium 4
Monitoring and Titration Strategy
Two acceptable approaches exist, though recent evidence favors clinical assessment:
Option 1: Train-of-Four (TOF) Monitoring
Option 2: Clinical Assessment Alone
- Equally effective as TOF monitoring for recovery time and drug dosing 5
- Monitor for: absence of spontaneous respirations, patient-ventilator synchrony, adequate oxygenation
- A 2004 randomized trial found no difference in recovery time (45 vs 38 minutes) or total drug dose between TOF monitoring and clinical assessment 5
Important caveat: While TOF monitoring may be useful as part of comprehensive assessment, it should not be used in isolation 6. The 2016 guidelines suggest against using TOF alone, recommending it only when incorporated into broader clinical evaluation 6.
Fixed-Dose vs. Titrated Strategies
Recent evidence strongly favors titrated dosing over fixed-dose protocols:
- Fixed-dose regimens (typically 5-6 mcg/kg/min) result in 3-fold higher drug consumption without improving oxygenation 7, 8
- A ventilator synchrony protocol using clinical titration required significantly less drug (415 mg vs 665 mg vs 1730 mg) compared to TOF-only or fixed-dose strategies, with equivalent efficacy 9
- Recommendation: Use titrated dosing starting at 2.5-3 mcg/kg/min and adjust based on clinical response rather than fixed high-dose protocols 7, 8, 9
Special Considerations
Volatile Anesthetic Interactions
- Isoflurane or enflurane (at 1.25 MAC) may prolong duration of action 1, 2
- Reduce infusion rate by 30-40% during stable volatile anesthetic administration 2
- Greater reductions may be needed with longer exposure 1
Hypothermia
- During therapeutic hypothermia (25-28°C), infusion requirements may be reduced by approximately 50% 2
- This is based on atracurium data but expected to apply to cisatracurium given structural similarity 2
Obesity
- Use ideal body weight (IBW) or adjusted body weight rather than actual body weight for dose calculations 6
- Recent data in obese ARDS patients shows IBW-based dosing uses less drug without compromising oxygenation improvement 10
ARDS-Specific Dosing
- For moderate-severe ARDS (PaO₂/FiO₂ <150), the landmark ACURASYS trial used: 15 mg bolus followed by 37.5 mg/hour (fixed rate) for 48 hours 11
- However, titrated strategies are now preferred based on more recent evidence showing equivalent efficacy with less drug exposure 7, 8, 9
Recovery Characteristics
- Recovery to TOF ratio >0.7 occurs in 34-85 minutes after discontinuation 1
- Recovery time is independent of infusion duration and organ function 1
- Mean recovery time: approximately 50-60 minutes in ICU patients 3, 4
- This is significantly faster than vecuronium and similar to atracurium 1
Critical Safety Points
- Always ensure adequate sedation and analgesia before initiating neuromuscular blockade 1, 6
- Cisatracurium produces no cardiovascular effects at therapeutic doses (no histamine release, no changes in heart rate or blood pressure) 1
- Prolonged weakness has been reported following cisatracurium use, though less commonly than with steroid-based agents 1
- Contains benzyl alcohol - use caution in neonates 2